NEW YORK, April 30, 2020 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today
announced a reminder to the Company's stockholders that today,
April 30, 2020, is the record date
for the previously announced distribution to our stockholders of
shares of common stock of Hoth Therapeutics, Inc. ("Hoth").
Each stockholder of the Company, as of 4:00
p.m. Eastern Time on April 30,
2020, is entitled to receive one (1) share of Hoth common
stock for every five hundred (500) shares of AIkido common stock
held. The original ratio of seventy (70) shares was changed
to reflect the increase in the number of Company shares issued and
outstanding, as of today's record date. The Company expects
to distribute the shares of Hoth common stock on May 4, 2020.
The Company will not distribute fractional shares of Hoth common
stock, and any fractional shares will be rounded down to the
nearest whole share. Stockholders of the Company do not need
to take any action to receive the shares of Hoth common stock,
other than be a stockholder of record on April 30, 2020, and stockholders do not need to
pay any consideration for, surrender or exchange shares of AIkido
common stock.
About AIkido
AIkido was initially formed in 1967 and is a biotechnology
company with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/notice-of-record-date-of-hoth-distribution-301050481.html
SOURCE AIkido Pharma Inc.